Dean Capital Investments Management LLC Acquires New Holdings in Unity Biotechnology Inc (UBX)
Dean Capital Investments Management LLC acquired a new position in shares of Unity Biotechnology Inc (NASDAQ:UBX) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 36,036 shares of the company’s stock, valued at approximately $543,000.
Separately, Gilder Gagnon Howe & Co. LLC purchased a new position in shares of Unity Biotechnology in the 2nd quarter valued at about $301,000. Institutional investors and hedge funds own 9.04% of the company’s stock.
Shares of Unity Biotechnology opened at $15.75 on Friday, according to MarketBeat.com. Unity Biotechnology Inc has a 1 year low of $12.75 and a 1 year high of $20.48.
UBX has been the subject of several recent research reports. Citigroup initiated coverage on Unity Biotechnology in a research note on Tuesday, May 29th. They issued a “buy” rating and a $32.00 price objective for the company. Goldman Sachs Group initiated coverage on Unity Biotechnology in a research note on Tuesday, May 29th. They issued a “neutral” rating and a $17.00 price objective for the company. Finally, Morgan Stanley initiated coverage on Unity Biotechnology in a research note on Tuesday, May 29th. They issued an “overweight” rating and a $25.00 price objective for the company.
About Unity Biotechnology
Unity Biotechnology, Inc, a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases.
Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers
Want to see what other hedge funds are holding UBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Unity Biotechnology Inc (NASDAQ:UBX).
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.